| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7335799 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2025
(1 year, 7 months from now) | |
| US11613511 | ESPERION THERAPS INC | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(16 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10118881 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(4 months ago) | |
| US8497301 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(4 months ago) | |
| US10941095 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(4 months ago) | |
| US9000041 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(4 months ago) | |
| US9624152 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(4 months ago) | |
| US11760714 | ESPERION THERAPS INC | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(16 years from now) | |
Nexletol is owned by Esperion Theraps Inc.
Nexletol contains Bempedoic Acid.
Nexletol has a total of 8 drug patents out of which 5 drug patents have expired.
Expired drug patents of Nexletol are:
- US10118881
- US8497301
- US10941095
- US9000041
- US9624152
Nexletol was authorised for market use on 21 February, 2020.
Nexletol is available in tablet;oral dosage forms.
Nexletol can be used as use of nexletol as an adjunct to diet and maximally tolerated statin therapy for inhibiting cholesterol synthesis to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease, use of nexletol as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease.
Drug patent challenges can be filed against Nexletol from 22 February, 2024.
The generics of Nexletol are possible to be released after 19 June, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 21, 2025 |
Drugs and Companies using BEMPEDOIC ACID ingredient
NCE-1 date: 22 February, 2024
Market Authorisation Date: 21 February, 2020
Treatment: Use of nexletol as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular dise...
Dosage: TABLET;ORAL
NEXLETOL family patents
